Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Engraftment, Persistence & Trafficking Analysis
Are you currently facing challenges in achieving robust, long-term persistence, predictable biodistribution, or complex trafficking of your advanced cell therapy products? Our Creative Biolabs NHP Applications in Engraftment, Persistence & Trafficking Analysis helps you accelerate development and maximize therapeutic durability through advanced recombinant cell engineering technology, high-throughput screening platforms, and longitudinal tracking assays in immunocompetent models.
Ensure Durable Therapeutic Efficacy with NHP Models
NHP models provide essential translational data on long-term survival, biodistribution, and stability of engineered cells, addressing early failures like immune rejection and poor expansion.
Overview of NHP Applications in Cell Therapy
What Are Our Research Areas?
The central challenge in translating modern cell therapies—such as CAR-T cells, TCR T cells, and iPSC-derived cell products—is ensuring their functional persistence and precise trafficking in vivo. For a therapy to achieve curative potential, the therapeutic payload (the engineered cell) must survive the host immune response, proliferate, successfully traffic to complex anatomical sites (like solid tumors, the central nervous system, or latent viral reservoirs), and remain functional over the intended therapeutic window. Preclinical failures are often rooted in a lack of durability, expansion, or targeted delivery. Creative Biolabs focuses on accurately characterizing these dynamics to de-risk your lead candidates.
Why Choose Us?
NHPs offer an irreplaceable platform for advanced cell therapy analysis, providing the highest fidelity to the human physiological environment before First-in-Human trials. Creative Biolabs leverages these unique advantages to deliver predictive data:
- Genetic/Immunological Similarities: NHPs possess a highly complex, immunocompetent immune system, closely mirroring human immune responses, cytokine profiles, and antigen presentation pathways—a critical factor when assessing potential immune rejection or toxicity associated with long-term cell engraftment.
- Clinical Translational Relevance: The larger size and complex organ systems (including distinct secondary lymphoid tissue structures) allow for clinically relevant dosing, administration routes, and monitoring techniques, vastly improving the prediction of safety and efficacy barriers like CRS.
- Long-Term, Multilineage Engraftment: NHPs are the gold standard for rigorously evaluating the long-term engraftment and differentiation of genetically modified hematopoietic stem cells (HSPCs) and CAR T cells into multiple blood lineages, a process that is highly distinct from rodent models.
- Data Types Required for Regulatory Submissions: Longitudinal persistence, biodistribution, and functional tracking data generated in NHPs are essential components frequently required by regulatory bodies for IND applications for cell therapies.
Fig.1 Migration and longevity of alloantigen-targeted chimeric antigen receptor regulatory T cells in NHPs.1
Key Applications
Creative Biolabs utilizes NHPs to address specific, high-risk questions concerning the Engraftment, Persistence, and Trafficking of your novel cell therapeutics.
- Long-Term CAR T-Cell Durability and Function: NHPs are used for pooled CAR-T screening, allowing head-to-head comparisons of novel CAR designs to identify candidates with superior proliferation, resistance to exhaustion.
- Assessing Stem Cell-Derived Product Engraftment: We track the multilineage repopulation and long-term survival of gene-edited or iPSC-derived products following autologous transplantation, validating the successful genetic modification and differentiation of long-term repopulating cells in a clinically relevant large animal model.
- Evaluating Trafficking to Specific Reservoirs: NHPs allow for the analysis of engineered cell trafficking to anatomically complex, antigen-sparse, or difficult-to-access sites, such as the brain, bone marrow, lymphoid organs, and latent viral reservoirs. This is critical for developing strategies to target chronic infectious diseases or solid tumors.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides an integrated suite of services designed specifically to quantify the long-term fate of your cell therapeutic agent in NHP models.
| Service Capability | Corresponding Application Area |
| Receptor Occupancy (Flow Cytometry) | Evaluates the functional status and target-binding capacity of infused cells or receptors on target cells in circulation and lymphoid tissues. |
| Tissue IHC/IF & In Situ Hybridization | Provides visual, localized evidence of where therapeutic cells have trafficked within specific organs (e.g., tumor microenvironment, spleen, liver). |
| Cytokine/Chemokine Multiplex Assays | Assesses cytokine release kinetics, a key indicator of in vivo CAR T-cell function and potential persistence-limiting inflammation or CRS. |
| Longitudinal & Repeat Sampling | Supports the necessary long-term blood, tissue, and fluid collection required to definitively prove durable therapeutic persistence and safety in NHPs. |
Translational Impact
Leveraging Creative Biolabs' NHP engraftment, persistence, and trafficking data fundamentally de-risks your clinical transition. By utilizing models with high biological relevance, we achieve a more reliable early proof of concept. Our detailed longitudinal monitoring allows for the early detection of potentially dose-limiting immune responses or toxicity (e.g., neutralizing antibodies, systemic inflammation) that small animal models fail to flag.
This predictive power is vital: NHP data on long-term engraftment, persistence, and functional tracking are often required for cell therapy IND submissions, providing necessary evidence that mitigates the risk of clinical hold. Partnering with Creative Biolabs means securing the high-quality, translational data needed to prove your product's durable safety and efficacy, reducing the overall risk of IND failure.
Frequently Asked Questions
Q: How does Creative Biolabs ensure accurate quantification of low-level persistent cells in NHP samples?
A: We employ highly sensitive quantitative methods, including ddPCR for engineered cell detection and highly multiplexed Flow Cytometry, paired with validated, NHP-specific probes and controls. These techniques offer superior resolution and sensitivity compared to traditional assays, enabling accurate tracking of even low-level therapeutic payloads persisting over long study durations.
Q: What types of NHP samples are required for long-term persistence and trafficking analysis?
A: For comprehensive analysis, we typically utilize a combination of sample types, including PBMCs, serum/plasma, CSF for CNS trafficking, and flash-frozen/FFPE tissue panels collected at various endpoints. Our Biological Collection & Biobanking services ensure the longitudinal integrity and stability of all collected specimens.
Q: Why do NHP models provide better persistence data for cell therapies than standard immunocompromised mouse models?
A: NHPs possess a fully intact and complex immunocompetent system. This allows us to accurately assess challenges inherent to therapeutic persistence, such as immune-mediated clearance, CAR T-cell exhaustion in an antigen-sparse environment, and the effects of chronic inflammation—factors that cannot be fully modeled in immunodeficient rodents. The NHP's long lifespan and physiological similarity are paramount for true long-term durability assessment.
Q: What is the typical turnaround time for persistence data, and how is the data reported?
A: Turnaround time is highly dependent on the complexity and duration of the study, particularly the required longitudinal time points. However, for bioanalysis samples, we adhere to strict internal timelines to provide data rapidly. All results are consolidated into an Integrated Bioinformatics Report, ensuring that quantification data, biomarker profiles, and histology images are presented in a comprehensive, regulatory-ready format for seamless review.
Contact Us
Creative Biolabs offers a decisive advantage in the development of cell therapies by providing robust, translational data on the engraftment, persistence, and trafficking of your therapeutic candidates in clinically relevant NHP models. Please reach out to our dedicated client services team today to learn how our integrated NHP platform can validate your lead candidates and significantly reduce your clinical development risk.
Reference
- Ellis, Gavin I., et al. "Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque." Cell Reports Medicine 3.5 (2022). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1016/j.xcrm.2022.100614